X hits on this document

613 views

0 shares

0 downloads

0 comments

12 / 170

11

FDA about these proceedings. However, FDA will refrain from discussing the details of

12

this meeting with the media until its conclusion. A press conference will be held in the

13

Sovereign Room immediately following the meting today. Also the committee is

14

reminded to please refrain from discussing the meeting topic during breaks or lunch.

15

Thank you.

2

meeting, there are often a variety of opinions, some of which are quite strongly held. Our

3

goal is that today’s meeting will be a fair and open forum for discussion of these issues

4

and individuals can express his/her views without interruption. Thus, as a gentle

5

reminder, individuals will be allowed to speak into the record only if recognized by the

6

Chair. We look forward to a productive meeting.

19

Endocrinologic and Metabolic Drugs Advisory Committee under the authority of the

20

Federal Advisory Committee Act of 1972. With the exception of the industry

21

representative, all members and temporary voting members are Special Government

22

Employees (SGEs) or regular Federal employees from other Agencies and are subject to

23

Federal conflict of interest laws and regulations.

Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com

8

in the Sunshine Act, we ask that the Advisory Committee members take care that their

9

conversations about the topic at hand take place in the open forum of the meeting.

16

CONFLICT OF INTEREST STATEMENT

17

PAUL TRAN, R.PH.

1

DR. BURMAN: For a topic, such as those being discussed at today’s

11

7

10

In the spirit of the Federal Advisory Committee Act and The Government

We are aware that members of the media are anxious to speak with the

18

The Food and Drug Administration is convening today’s meeting of the

Document info
Document views613
Page views613
Page last viewedThu Jan 19 07:40:24 UTC 2017
Pages170
Paragraphs7975
Words54271

Comments